A comparative study of brain atrophy by computerized tomography in chronic renal failure and chronic hemodialysis

Sulfinpyrazone can reduce the incidence of thrombosis of A-V shunts in chronic renal failure. The drug is also reported to prevent acute deaths from coronary artery disease. This study was to determine mechanisms for these protective effects.Patients on chronic hemodialysis served as the study models. Six patients on dialysis three times per week for 6 or more months received sulfinpyrazone 200 mgm t.i.d. p.o. for 14 days. Blood samples were obtained before dialysis was begun before and after the 14 days of drug therapy.Results are shown as mean ± standard error of mean.AT III levels rose significantly by functional and immune assays. Functional levels (by von Kaulla technique) rose 24.5 ± 3.1 sec. to 47.3 + 5.5 sec. (P>.005) Plasma protein AT III (by radial immunodiffusion) rose 31.2 ± 2.17 mg/dl to 37.9 ± 2.1 mgm/dl. (P>.01) Platelet factor 4 (by Abbot radioimmunology assay) fell from 46.4 + 13.6 ngm/ml to 9.5 ± 1.1 ngm/ml.(P>.005) The concentration of thrombin-anti-thrombin complex (by R. Rosenberg, Harvard Medical School, Boston) rose from 4.2 ± .09 to 8.4 ± 1.0 (P>.005)Thus it appears that sulfinpyrazone elevates antithrombin concentration and function while simultaneously suppressing platelet release. These two effects may or may not be mutually dependent. The clinical efficacy of sulfinpyrazone may relate in part to the elevation of antithrombin III, probably by inhibiting its consumption, while also inhibiting platelet function.

Download Full-text

Anemia in Sudanese patients with chronic renal failure (CRF) and in patients undergoing chronic hemodialysis

Bangladesh Journal of Medical Science ◽

10.3329/bjms.v10i3.8357 ◽

1970 ◽

Vol 10 (3) ◽

pp. 152-158

Author(s):

MH Fathelrahman

Keyword(s):

Renal Failure ◽

Chronic Renal Failure ◽

Chronic Hemodialysis ◽

Hemoglobin Level ◽

Adverse Outcomes ◽

Teaching Hospitals ◽

Factors Associated ◽

Serum Erythropoietin Level ◽

The Mean ◽

Serum Erythropoietin

Background: The term of anemia of chronic renal failure (CRF) in sufficiency refers to that anemia resulting directly from failure of the endocrine and excretory functions of the kidney and decreased production of erythropoietin by damaged kidneys. The serum erythropoietin level in patients with renal failure does not increase in response to the developing anemia, which is the primary cause of inadequate erythropoiesis. Aim: The purpose of our study was to examine, among patients with CRF, the combined association of CRF and anemia on adverse outcomes. Settings and Design: A hospitalized study using administrative data, we identified all patients hospitalized with CRF in IBN-Sena hospital and Khartoum teaching hospitals, Khartoum, Sudan. Materials and Methods: This was a retrospective cohort study of 500 patients having a diagnosis of chronic renal failure hospitalized and discharged between October 2007 to February 2010 from two Sudanese Teaching hospitals (Khartoum and IBN-Sena). All adult patients with chronic renal failure hospitalized for hemodialysis. Results: Hemoglobin level was recorded for 500 members (100%) of the cohort. The mean (SD) hemoglobin was 13.0 g/dL (2.2) range from 11.8 g/dL to 14.6 g/dL. On admission, an hemoglobin of ≥ 14 g/dL was found in 36.2% of the patients, 36.2% had an hemoglobin between 12 g/dL and 14 g/dL, 19.6% between 10 g/dL and 12 g/dL, and 8% ≤ 10 g/dL. The proportion of patients with CRF was associated with increasing anemia. Conclusion: The results obtained indicated the further evidence that the concomitant presence of either CRF or anemia increased the risk of dying in the hospital or of being readmitted within 30 days among patients hospitalized. The association persisted after controlling for other factors associated with adverse outcomes in these patients. Key words: Anemia, chronic renal failure. DOI: http://dx.doi.org/ 10.3329/bjms.v10i3.8357 BJMS 2011; 10(3): 152-158

Download Full-text

Effects of Chronic Renal Failure on Surgical Outcomes of Laparoscopic Nephrectomy for Benign Diseases? A Comparative Study

Journal of Urological Surgery ◽

10.4274/jus.galenos.2019.3066 ◽

2020 ◽

Vol 7 (1) ◽

pp. 50-53

Author(s):

Erkan Ölçücüoğlu ◽

Muhammet İrfan Dönmez ◽

Ahmet Murat Bayraktar

Keyword(s):

Renal Failure ◽

Chronic Renal Failure ◽

Comparative Study ◽

Surgical Outcomes ◽

Laparoscopic Nephrectomy ◽

Benign Diseases

Download Full-text

A comparative study of pre and post dialysis biochemical parameters in chronic renal failure patients

International Journal of Clinical Biochemistry and Research ◽

10.18231/j.ijcbr.2020.044 ◽

2020 ◽

Vol 7 (2) ◽

pp. 204-206

Author(s):

Vinod V Wali ◽

◽

Gouri A Gulavan ◽

Vimmi Kishore ◽

◽

...

Keyword(s):

Renal Failure ◽

Chronic Renal Failure ◽

Comparative Study ◽

Biochemical Parameters

Download Full-text

Decrease of serum paraoxonase activity in chronic renal failure.

Journal of the American Society of Nephrology ◽

10.1681/asn.v9112082 ◽

1998 ◽

Vol 9 (11) ◽

pp. 2082-2088

Author(s):

T F Dantoine ◽

J Debord ◽

J P Charmes ◽

L Merle ◽

P Marquet ◽

...

Keyword(s):

Renal Failure ◽

Peritoneal Dialysis ◽

Chronic Renal Failure ◽

Chronic Hemodialysis ◽

Phenyl Acetate ◽

Paraoxonase Activity ◽

Control Subjects ◽

Transplant Patients ◽

End Stage ◽

Serum Paraoxonase

Paraoxonase is an esterase that hydrolyzes organophosphate compounds. The enzyme is associated with HDL and could protect LDL against peroxidation, which suggests a possible involvement of paraoxonase in the antiatherogenic properties of HDL. Paraoxonase activity has been shown to be low in patients with myocardial infarction, diabetes mellitus, or familial hypercholesterolemia. Because cardiovascular disease is the main cause of death in chronic renal failure, serum paraoxonase activity was measured by spectrophotometry using three synthetic substrates (phenyl acetate, paraoxon, and 4-nitrophenyl acetate) in 305 patients with kidney disease, including 47 patients with non-end-stage chronic renal failure, 104 patients treated with hemodialysis, 22 patients treated with peritoneal dialysis, and 132 renal transplant patients. Patients were compared with two groups of aged-matched control subjects (total number = 195). Especially with 4-nitrophenyl acetate, paraoxonase activity was lower in patients with some degree of renal insufficiency (chronic renal failure [P < 0.05], chronic hemodialysis [P < 10(-4)], chronic peritoneal dialysis [P < 10(-4)]) than in control subjects. In transplant patients, paraoxonase activity was not found to be different from that in control subjects. The decrease of paraoxonase activity and thus the reduction of its antiatherogenic properties in renal failure could be an essential factor of premature vascular aging, especially when dialysis is used. Renal transplantation seems to restore paraoxonase activity.

Download Full-text